dr. tolaney on activity with abemaciclib in patients with hr /her2– breast cancer
Published 7 years ago • 252 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:55
dr. tolaney on abemaciclib plus pembrolizumab for hr , her2- breast cancer
-
1:00
dr. tolaney on remaining questions with cdk4/6 inhibitors in hr /her2- breast cancer
-
1:39
dr. tolaney on novel approaches in treating her2-positive breast cancer
-
0:49
dr. tolaney on the current treatment landscape for her2 breast cancer
-
1:20
dr tolaney on ongoing clinical trials in early-stage her2 breast cancer
-
1:25
dr. tolaney on the neoadjuvant therapy for her2-positive breast cancer
-
7:37
dr. tolaney highlights new breast cancer combination therapies
-
1:44
dr. tolaney on the atempt trial for her2 breast cancer
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
-
1:39
dr tolaney on standard frontline treatment approaches in her2 breast cancer
-
1:20
dr tolaney on the potential role for biomarkers in early-stage her2 breast cancer
-
1:39
dr. tolaney on sequencing strategies in metastatic her2 breast cancer
-
2:00
dr sara m. tolaney: challenges with treating, role of clinical trials in her2-positive breast cancer
-
1:53
dr. tolaney on navigating adjuvant therapy in early-stage her2 breast cancer
-
1:08
4-year monarche results: increasing benefits with abemaciclib et for er /her2- high-risk early bc
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
1:32
dr. tolaney on the evolution of treatment in her2 breast cancer
-
2:55
clinical activity of abemaciclib in patients with r/r mcl
-
5:12
monarch 2: abemaciclib added to fulvestrant shows os benefit in hr /her2- advanced breast cancer